Interim report January – June 2023 for CombiGene AB (publ)
August 25, 2023
April – June 2023• Net sales: TSEK 1,788 (4,738).• Other operating revenues: TSEK 1,413 (9,800).• Profit
April – June 2023• Net sales: TSEK 1,788 (4,738).• Other operating revenues: TSEK 1,413 (9,800).• Profit
CombiGene AB (“CombiGene”, the “Company”) today announces that CEO Jan Nilsson will leave his position as
The following resolutions were passed at the annual general meeting (the “AGM”) of CombiGene AB (publ)
January – March 2023• Net sales: TSEK 2,168 (11,403).• Other operating revenues: TSEK 0 (2,801).• Profit
CombiGene announces that the annual report now is available on the Company´s homepage, www.combigene.com, and as
The shareholders of CombiGene AB (publ) reg. no. 556403-3818 (the “Company”) are hereby summoned to attend
October – December 2022• Net sales: TSEK 5,346 (84,042).• Other operating revenues: TSEK 674 (1,098).• Profit
October – December 2022• Net sales: TSEK 5,346 (84,042).• Other operating revenues: TSEK 674 (1,098).• Profit
STOCKHOLM — January 9, 2023. CombiGene AB (“CombiGene”, the “Company”) and the Danish company Zyneyro ApS
July – September 2022• Net sales: 5,213 (0) TSEK.• Other operating revenues: 8,313 (423) TSEK.• Profit